JEADVRCT
Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial.
ConclusionIn adults with moderate AD post-TCS and -TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream significantly improved clinical signs of AD, rapidly improved itch and was well tolerated. Thus, ruxolitinib cream may represent an effective topical option before escalation to systemic therapy in patients with moderate AD.
Carrascosa JM, Prajapati VH, … senior author Wollenberg AJournal of the European Academy of Dermatology and Venereology